PHASE I/II STUDY OF ERLOTINIB AND TEMSIROLIMUS (CCI-779) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)

被引：0
|
作者：
Wen, Patrick [1 ]
Kuhn, John [2 ]
Chang, Susan [3 ]
Lamborn, Kathleen [3 ]
Robbins, Hi [4 ]
Cloughesy, Timothy [5 ]
Lieberman, Frank [6 ]
Mehra, Minesh [7 ]
Gilbert, Mark
Cooper, Josh
Drappatz, Jan [8 ]
Kesari, Santosh
Norden, Andrew
Groves, Morris [9 ]
Aldape, Kenneth [9 ]
Yung, W. K. Alfred [9 ]
Dancey, Janet [10 ]
Prados, Michael [3 ]
机构：
[1] Ctr Neurooncol, Boston, MA USA
[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] Univ Wisconsin, Madison, WI USA
[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] NCI, Bethesda, MD 20892 USA
来源：
NEURO-ONCOLOGY | 2008年 / 10卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：824 / 824
页数：1
相关论文
共 50 条
  • [41] NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas.
    Lieberman, FS
    Cloughesy, T
    Fine, H
    Kuhn, J
    Lamborn, K
    Malkin, M
    Robbins, HI
    Yung, WA
    Wen, P
    Prados, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 109S - 109S
  • [42] Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03)
    Wen, P. Y.
    Puduvalli, V.
    Kuhn, J.
    Reid, J.
    Cloughesy, T.
    Yung, W. A.
    Chang, S. M.
    Robbins, H. I.
    McGovern, R.
    Ames, M.
    Prados, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Phase I study of vorinostat (suberoylanilide hydroxamic acid [SAHA]) in combination with temozolomide in patients with malignant gliomas (NABTC 04-03)
    Wen, Patrick
    Puduvalli, Vinay
    Kuhn, John
    Reid, Joel
    Cloughesy, Timothy
    Yung, Wka
    Drappatz, Jan
    Lamborn, Kathleen
    Gilbert, Mark
    Butowski, Nicholas
    Levin, Victor
    Chang, Susan
    Kesari, Santosh
    Robbins, Hi
    McGovern, Renee
    Richon, Victoria
    Frankel, Stanley
    Ames, Matthew
    Zweibel, James
    Prados, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 518 - 518
  • [44] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] A PHASE 2 STUDY OF SAFETY AND EFFICACY OF TEMSIROLIMUS (CCI-779) ADMINISTERED AS A SINGLE AGENT IN EAST ASIAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
    Sun, Y.
    Rha, S. Y.
    Lee, S.
    Guo, J.
    Ueda, T.
    Qin, S.
    Naito, S.
    Cincotta, M.
    Tokushige, K.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 290 - 290
  • [46] Molecular inhibition of mTOR with temsirolimus (TORISEL™, CCI-779) is a promising strategy in relapsed NHL:: The University of Chicago phase II consortium.
    Smith, Sonali M.
    Pro, Barbara
    Smith, Scott
    Stiff, Patrick
    Lester, Eric
    Modi, Sanjiv
    van Besien, Koen
    BLOOD, 2006, 108 (11) : 703A - 704A
  • [47] Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors.
    Haas, N. B.
    Lewis, N.
    Cohen, R. B.
    Malizzia, L.
    Einarson, M. B.
    Walker, M. A.
    Kim, T.
    Von Mehren, M.
    Hudes, G. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 137S - 137S
  • [48] Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein
    Hofmeister, Craig C.
    Yang, Xiaoxia
    Pichiorri, Flavia
    Chen, Ping
    Rozewski, Darlene M.
    Johnson, Amy J.
    Lee, Seungsoo
    Liu, Zhongfa
    Garr, Celia L.
    Hade, Erinn M.
    Ji, Jia
    Schaaf, Larry J.
    Benson, Don M., Jr.
    Kraut, Eric H.
    Hicks, William J.
    Chan, Kenneth K.
    Chen, Ching-Shih
    Farag, Sherif S.
    Grever, Michael R.
    Byrd, John C.
    Phelps, Mitch A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3427 - 3434
  • [49] Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
    Merchan, J. R.
    Liu, G.
    Fitch, T.
    Picus, J.
    Qin, R.
    Pitot, H. C.
    Maples, W.
    Erlichman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] A phase IINCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC
    Molina, Julian R.
    Mandrekar, Sumithra J.
    Rowland, Kendrith
    Reuter, Nicholas F.
    Jett, James R.
    Marks, Randolph
    Schild, Stevens E.
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S413 - S413
12345